A Preliminary Assessment of the Critical Differences Between Novel Oral Anticoagulants Currently in Development
- 1 September 2005
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (9) , 1004-1017
- https://doi.org/10.1177/0091270005278084
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Anticoagulation Therapy for Stroke Prevention in Atrial FibrillationJAMA, 2003
- Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial FibrillationNew England Journal of Medicine, 2003
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001
- Antithrombotic Therapy in Valvular Heart DiseaseChest, 2001
- Antithrombotic Therapy To Prevent Stroke in Patients with Atrial FibrillationAnnals of Internal Medicine, 1999
- Is Warfarin Underused in the Treatment of Elderly Persons With Atrial Fibrillation?Archives of internal medicine (1960), 1997
- Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trialThe Lancet, 1996
- An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1996
- Acenocoumarol and Heparin Compared with Acenocoumarol Alone in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1992
- NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSISThe Lancet, 1985